EPO published patent EP4545138A1 granting protection for heterocyclic BLT2 agonist compounds and their medical applications. The patent names Fraunhofer-Gesellschaft and Goethe University Frankfurt as applicants, with designated states covering 38 European countries including Germany, France, UK, Italy, Spain, and other EPO member states. The compounds are classified under multiple C07D heterocyclic categories and are intended for dermatological (A61P 17/00) and analgesic (A61P 29/00) applications.

This is a routine patent publication that creates intellectual property rights rather than regulatory obligations. Pharmaceutical companies developing BLT2-targeted therapies should conduct freedom-to-operate analyses to assess potential infringement risks. No compliance actions or deadlines apply to this publication. Competitors seeking to develop similar compounds will need to either license the technology or design around the claims.